Kaspa's KCC-20 fungible-token standard is in its final review stage, known as Last Call, but its adoption and impact remain uncertain. The weekly price chart suggests potential rebound levels for KAS at $0.19, $0.13, $0.075, and $0.05, though no rebound is confirmed. Kaspa's recent Toccata upgrade added new features like covenants and zero-knowledge verification but has not yet increased application use, transaction demand, or fee revenue. Network activity actually declined during a period of KAS price strength, highlighting the need for completed KCC-20 review and evidence of real application use to confirm any positive price movement.
Kaspa's KCC-20 fungible-token standard is in its final review stage, providing context for cryptocurrency market activity. For readers following major cryptocurrencies on Pluang, here is the market snapshot as of Oct 20, 2026 07:21 WIB: out of 50 priced assets, 32 rose and 17 fell today. Notable movers include BAL (Balancer) at Rp16.297 with a 1-day change of +11.14%, BAT (Basic Attention Token) at Rp3.477 with +10.29%, and EOS (EOS.IO) at Rp12.649 with +8.13%. Typical hold times range from 85 to 93 days for these assets.
Anteris Technologies received regulatory approval from Germany's BfArM to start enrolling patients in its global PARADIGM trial for the DurAVR Transcatheter Heart Valve. This approval allows the company to recruit patients at leading German centers, ...
XBiotech announced positive final efficacy results from its phase II TASKIN trial for vilamakitug (XB2001) in refractory metastatic colorectal cancer. The study, funded by the French National Cancer Institute, showed a 61.3% overall survival rate at ...
XBiotech announced positive final results from the Phase II TASKIN study, showing that adding Vilamakitug (XB2001) to standard chemotherapy improved 12-month overall survival to 61.3% in patients with refractory metastatic colorectal cancer, surpassi...
Nvidia announced a nearly $10 billion investment plan to support Europe's AI ecosystem, focusing on four German startups: Agile Robots, Avelios Medical, Mirelo, and Reflex Aerospace. This move aligns with Germany's goal to lead in industrial AI, with...
Recce Pharmaceuticals has reached a key milestone in its Phase 3 trial for treating diabetic foot infections with its RECCE® 327 Gel (R327G). An independent Data Monitoring Committee will review unblinded data from 75 patients, following encouraging ...
